PIQ
Director Trades
| Date | Director | Value |
|---|
Company News
Proteomics International Gains ISO 15189 Certification for Precision Diagnostics Operations
Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]
Proteomics International Laboratories launches PromarkerD predictive test for diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. Diabetes is the leading […]
Proteomics International Laboratories’ PromarkerD test paving the way for early detection of diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currently accounts for around 10% of the nation’s diabetes cases and cannot be prevented. Globally, diabetes has emerged as the largest single […]
Proteomics International partners with University of Oxford to advance endometriosis study
Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis. The samples will be used to further clinically validate the performance of the company’s PromarkerEndo diagnostic models for detecting the disease. Analysis is expected to be […]
Proteomics commences European campaign to advance PromarkerD diabetic kidney disease test
Proteomics International Laboratories (ASX: PIQ) has embarked on a European commercialisation campaign following the launch of PromarkerD – its predictive diagnostic test for diabetic kidney disease – in Spain. The Spanish launch marks the first European country where the test will be available and sets the stage for broader geographic distribution in the coming months. […]
Proteomics signs collaborate agreement with US pharma giant to advance PromarkerD
Medical technology company Proteomics International Laboratories (ASX: PIQ) has advanced the application of its ground-breaking predictive diagnostic test, PromarkerD, by signing a research collaboration agreement with US pharmaceutical company Janssen Research & Development, a subsidiary of one of the world’s largest companies, Johnson & Johnson. The ASX-listed company says it at the forefront of what’s known […]
Proteomics advances PromarkerD platform and prepares to ship first batch of immunoassay kits
Medical technology company Proteomics International Laboratories (ASX: PIQ) has hatched plans to distribute the first commercial batches of its new “PromarkerD” immunoassay kits, with first shipments scheduled for 20 November 2018. “This follows completion of production of the key antibody reagents in Puerto Rico, and manufacture of the kit in certified facilities in California, both […]
Proteomics secures deal to market diabetic kidney disease test in Spain
Proteomics International Laboratories (ASX: PIQ) has clinched a licence deal to market its diabetic kidney disease prediction test in Spain, where around 3.6 million adults have been diagnosed with diabetes. The medical technology company today announced the deal with Patia Europe, the Spanish subsidiary of public health company Patia Biopharma Mexico. It already has a […]
Proteomics focuses on analytics and advances towards cash flow positive status
Proteomics International Laboratories (ASX: PIQ) has secured a major commercial contract which propels the company into “nearing” cash flow positive status. Earlier this morning, the medical technology company announced it had secured a contract with Dutch/Australian company BiosanaPharma to conduct an analytical comparability study on a drug treatment for allergic asthma. The contract is Proteomics’ […]
Proteomics’ predictive diabetes test to be sold in US and could soon be coming to Australia
Medical technology company Proteomics International Laboratories (ASX: PIQ) has announced a significant commercial development this morning with the news that its novel predictive diagnostics PromarkerD diabetes-detection test would be marketed and distributed in the United States. The US is currently regarded as the largest market for diabetes in the world with over 30 million people […]
